Pirin is reported as a biomarker in breast cancer, which is abnormal and irregular proliferation of cells associated with inappropriate stimulation of pathways involved in signal transduction (Feitelson et al., 2015; Riaz et al., 2017; Chang et al., 2019). Here, PIR is linked to breast cancer.